title: Harms versus benefits with duration of androgen suppression.
authors.affiliation: Department of Radiation Oncology, Dana-Farber and Brigham and Women's Cancer Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. pnguyen@LROC.harvard.edu
authors.forename: Paul L
authors.initials: PL
authors.lastname: Nguyen
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001918:Brachytherapy; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D016729:Leuprolide